These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
387 related items for PubMed ID: 11967569
1. Structural insights into the pro-apoptotic function of mitochondrial serine protease HtrA2/Omi. Li W, Srinivasula SM, Chai J, Li P, Wu JW, Zhang Z, Alnemri ES, Shi Y. Nat Struct Biol; 2002 Jun; 9(6):436-41. PubMed ID: 11967569 [Abstract] [Full Text] [Related]
2. Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways. Suzuki Y, Takahashi-Niki K, Akagi T, Hashikawa T, Takahashi R. Cell Death Differ; 2004 Feb; 11(2):208-16. PubMed ID: 14605674 [Abstract] [Full Text] [Related]
3. Specific protein interaction of human Pag with Omi/HtrA2 and the activation of the protease activity of Omi/HtrA2. Hong SK, Cha MK, Kim IH. Free Radic Biol Med; 2006 Jan 15; 40(2):275-84. PubMed ID: 16413409 [Abstract] [Full Text] [Related]
4. The mitochondrial serine protease HtrA2/Omi: an overview. Vande Walle L, Lamkanfi M, Vandenabeele P. Cell Death Differ; 2008 Mar 15; 15(3):453-60. PubMed ID: 18174901 [Abstract] [Full Text] [Related]
5. The mitochondrial serine protease HtrA2/Omi cleaves RIP1 during apoptosis of Ba/F3 cells induced by growth factor withdrawal. Vande Walle L, Wirawan E, Lamkanfi M, Festjens N, Verspurten J, Saelens X, Vanden Berghe T, Vandenabeele P. Cell Res; 2010 Apr 15; 20(4):421-33. PubMed ID: 20125124 [Abstract] [Full Text] [Related]
6. Random mutagenesis of PDZ(Omi) domain and selection of mutants that specifically bind the Myc proto-oncogene and induce apoptosis. Junqueira D, Cilenti L, Musumeci L, Sedivy JM, Zervos AS. Oncogene; 2003 May 08; 22(18):2772-81. PubMed ID: 12743600 [Abstract] [Full Text] [Related]
7. Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice. Jones JM, Datta P, Srinivasula SM, Ji W, Gupta S, Zhang Z, Davies E, Hajnóczky G, Saunders TL, Van Keuren ML, Fernandes-Alnemri T, Meisler MH, Alnemri ES. Nature; 2003 Oct 16; 425(6959):721-7. PubMed ID: 14534547 [Abstract] [Full Text] [Related]
8. The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. van Loo G, van Gurp M, Depuydt B, Srinivasula SM, Rodriguez I, Alnemri ES, Gevaert K, Vandekerckhove J, Declercq W, Vandenabeele P. Cell Death Differ; 2002 Jan 16; 9(1):20-6. PubMed ID: 11803371 [Abstract] [Full Text] [Related]
9. Alzheimer's disease-associated amyloid beta interacts with the human serine protease HtrA2/Omi. Park HJ, Seong YM, Choi JY, Kang S, Rhim H. Neurosci Lett; 2004 Feb 26; 357(1):63-7. PubMed ID: 15036614 [Abstract] [Full Text] [Related]
10. The tumor suppressor WARTS activates the Omi / HtrA2-dependent pathway of cell death. Kuninaka S, Nomura M, Hirota T, Iida S, Hara T, Honda S, Kunitoku N, Sasayama T, Arima Y, Marumoto T, Koja K, Yonehara S, Saya H. Oncogene; 2005 Aug 11; 24(34):5287-98. PubMed ID: 16007220 [Abstract] [Full Text] [Related]
11. Structural and functional analysis of the ligand specificity of the HtrA2/Omi PDZ domain. Zhang Y, Appleton BA, Wu P, Wiesmann C, Sidhu SS. Protein Sci; 2007 Aug 11; 16(8):1738-50. PubMed ID: 17656586 [Abstract] [Full Text] [Related]
12. Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion. Liu HR, Gao E, Hu A, Tao L, Qu Y, Most P, Koch WJ, Christopher TA, Lopez BL, Alnemri ES, Zervos AS, Ma XL. Circulation; 2005 Jan 04; 111(1):90-6. PubMed ID: 15611365 [Abstract] [Full Text] [Related]
13. The serine protease Omi/HtrA2 is involved in XIAP cleavage and in neuronal cell death following focal cerebral ischemia/reperfusion. Althaus J, Siegelin MD, Dehghani F, Cilenti L, Zervos AS, Rami A. Neurochem Int; 2007 Jan 04; 50(1):172-80. PubMed ID: 16978742 [Abstract] [Full Text] [Related]
14. Serine protease Omi/HtrA2 targets WARTS kinase to control cell proliferation. Kuninaka S, Iida SI, Hara T, Nomura M, Naoe H, Morisaki T, Nitta M, Arima Y, Mimori T, Yonehara S, Saya H. Oncogene; 2007 Apr 12; 26(17):2395-406. PubMed ID: 17130845 [Abstract] [Full Text] [Related]
15. Mitochondrial import of Omi: the definitive role of the putative transmembrane region and multiple processing sites in the amino-terminal segment. Kadomatsu T, Mori M, Terada K. Biochem Biophys Res Commun; 2007 Sep 21; 361(2):516-21. PubMed ID: 17662244 [Abstract] [Full Text] [Related]
16. Intricate structural coordination and domain plasticity regulate activity of serine protease HtrA2. Chaganti LK, Kuppili RR, Bose K. FASEB J; 2013 Aug 21; 27(8):3054-66. PubMed ID: 23608143 [Abstract] [Full Text] [Related]
17. Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease. Bogaerts V, Nuytemans K, Reumers J, Pals P, Engelborghs S, Pickut B, Corsmit E, Peeters K, Schymkowitz J, De Deyn PP, Cras P, Rousseau F, Theuns J, Van Broeckhoven C. Hum Mutat; 2008 Jun 21; 29(6):832-40. PubMed ID: 18401856 [Abstract] [Full Text] [Related]
18. Binding specificity and regulation of the serine protease and PDZ domains of HtrA2/Omi. Martins LM, Turk BE, Cowling V, Borg A, Jarrell ET, Cantley LC, Downward J. J Biol Chem; 2003 Dec 05; 278(49):49417-27. PubMed ID: 14512424 [Abstract] [Full Text] [Related]
19. Tissue-specific splicing of Omi stress-regulated endoprotease leads to an inactive protease with a modified PDZ motif. Faccio L, Fusco C, Viel A, Zervos AS. Genomics; 2000 Sep 15; 68(3):343-7. PubMed ID: 10995577 [Abstract] [Full Text] [Related]
20. Distinct 3D Architecture and Dynamics of the Human HtrA2(Omi) Protease and Its Mutated Variants. Gieldon A, Zurawa-Janicka D, Jarzab M, Wenta T, Golik P, Dubin G, Lipinska B, Ciarkowski J. PLoS One; 2016 Sep 15; 11(8):e0161526. PubMed ID: 27571206 [Abstract] [Full Text] [Related] Page: [Next] [New Search]